Amanda Murphy focuses her practice on client counseling and patent prosecution for a range of clients including small start-up companies, research foundations, and large pharmaceutical companies.  Dr. Murphy prepares new patent applications, prosecutes U.S. and foreign applications, and represents applicants at appeals and oral hearings before the Patent Trial and Appeal Board of the U.S. Patent Trademark Office (PTAB) (formerly the U.S. Board of Patent Appeals and Interferences).She has experience in prosecuting inter partes and ex partes reexamination applications, reissue applications, and patent term extension applications for approved pharmaceuticals, including obtaining supplemental protection certificates in Europe.

In addition to her patent counseling and prosecution practice, Dr. Murphy has handled various litigation matters, including recently assisting a major pharmaceutical company in a district court litigation in which she worked with experts and assisted in developing infringement and validity opinions.  She also provides strategic advice and pre-litigation analysis, and prepares patentability, enforceability, and infringement opinions, and petitions for inter partes review.

Dr. Murphy’s technical experience includes anticancer agents, antibiotic susceptibility, antibodies, antiretrovirals, antipsychotics, bioethanol technology, blood clotting factors, cosmetics, diagnostic and detection systems, nucleic acid and protein technologies, Raman spectroscopy, recombinant organisms, small molecules, and vaccines.

Prior to joining Finnegan, Dr. Murphy received her Ph.D. from Cornell University, where she studied the molecular requirements for protein-lipid interactions during retroviral assembly and the lipid compositions of retroviral particles.  She then gained significant experience as a technical specialist and a student associate at Finnegan during her studies at Georgetown Law.  She also served as law clerk to the Honorable S. Jay Plager on the U.S. Court of Appeals for the Federal Circuit from 2011 to 2012.